Michael A. Incze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael A. Incze has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
A. Taylor Kelley
Division of General Internal Medicine, Department of Medicine, University of Utah School of Medicine, Salt Lake City
7 shared publicationsAdam J. Gordon
Program of Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA)
6 shared publications- Adam J. Gordon
Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
5 shared publications Laura Stolebarger
Program for Addiction Research, Clinical Care, Knowledge, and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City
5 shared publications- Alan Taylor Kelley
Division of General Internal Medicine, University of Utah , Salt Lake City, UT
4 shared publications Sophia Huebler
Program of Addiction Research, Clinical Care, Knowledge, and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City
4 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Wiley in Journal of Hospital Medicine
Hospitalist perspectives and practices in treating hospitalized patients with alcohol withdrawal syndrome in the era of phenobarbital re‐emergence
Medication treatment for moderate to severe alcohol withdrawal syndrome (AWS) is evolving, particularly with renewed phenobarbital use. However, little research has examined how hospitalists manage AWS. We conducted a multiple‐methods study involving hospitalists from a national US Hospital Medicine research network. Thirty‐three hospitalists from 27 tertiary hospitals completed surveys and participated in seven focus groups on August 8, 2025. Benzodiazepines remained the most common treatment, but phenobarbital use was reported in 67% of emergency departments and 44% of inpatient medical units. Four themes emerged: hospitalists are adaptable in responding to changing practices and drug shortages; a lack of consensus on AWS treatment practices leads to a “wild west approach” to therapy selection; hospitalists prioritize care‐delivery outcomes when selecting medications; and patients are minimally involved in shared decision‐making. Participants strongly supported additional research to guide evidence‐based AWS care. These findings highlight uncertainty and the need for standardized, patient‐centered approaches to AWS management.
- 4 October 2026
- Published by Wiley in Journal of Hospital Medicine
Open AccessHospitalist perspectives and practices in treating hospitalized patients with alcohol withdrawal syndrome in the era of phenobarbital re‐emergence
Medication treatment for moderate to severe alcohol withdrawal syndrome (AWS) is evolving, particularly with renewed phenobarbital use. However, little research has examined how hospitalists manage AWS. We conducted a multiple‐methods study involving hospitalists from a national US Hospital Medicine research network. Thirty‐three hospitalists from 27 tertiary hospitals completed surveys and participated in seven focus groups on August 8, 2025. Benzodiazepines remained the most common treatment, but phenobarbital use was reported in 67% of emergency departments and 44% of inpatient medical units. Four themes emerged: hospitalists are adaptable in responding to changing practices and drug shortages; a lack of consensus on AWS treatment practices leads to a “wild west approach” to therapy selection; hospitalists prioritize care‐delivery outcomes when selecting medications; and patients are minimally involved in shared decision‐making. Participants strongly supported additional research to guide evidence‐based AWS care. These findings highlight uncertainty and the need for standardized, patient‐centered approaches to AWS management.
- 1 October 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (13) , 1256-1257
The Mayor
- 1 October 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (13) , 1256-1257
The Mayor
- Open Access
- 24 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0359281
Feasibility of an interdisciplinary primary care-based intervention to improve care transitions for hospitalized patients with substance use disorders: The IntACT pilot randomized controlled trial protocol
Background: Hospitalizations are common among individuals with substance use disorders (SUD) and represent crucial opportunities to engage patients in treatment. Quality efforts to increase SUD treatment access in hospital settings must be paired with interventions that support linkage to follow-up SUD and medical care. However, the best way to support patients with SUD during transitions of care after hospitalization is unknown. Methods: The IntACT pilot study is a single-site randomized controlled trial that aims to assess the feasibility and preliminary effectiveness of a primary care-based Interdisciplinary Addiction Care Transition (IntACT) team. IntACT deploys from a partnering primary care clinic to the hospital to meet patients with SUD while they are admitted, then follows them after discharge for four months to facilitate linkage to and retention in follow-up care. The pilot study will randomize 75 hospitalized patients with SUD to receive IntACT or Usual Care, assessing both implementation and effectiveness outcomes over a six month study period. Primary outcomes include implementation measures (e.g., reach, acceptability, feasibility, and cost) assessed using a mixed methods approach, as well as preliminary measures of effectiveness including successful linkage to follow-up medical and/or SUD care after hospitalization and retention in treatment. Secondary effectiveness measures include time to first post-discharge follow-up visit, substance use patterns, and acute care utilization (e.g., hospital readmissions). The IntACT study will also enroll 20 clinicians from hospital and outpatient settings who interact with IntACT while providing patient care to provide input on intervention feasibility, appropriateness, and acceptability. Study design and procedural elements will also be assessed for feasibility and acceptability. Discussion: Identifying promising interventions to support transitions to follow-up SUD and medical care following hospitalization is imperative to increase SUD treatment access and improve care quality. The IntACT pilot study evaluates the feasibility of a novel, potentially scalable team-based care transition intervention, gathering implementation data from both patients and clinicians who are exposed to the intervention. The results of this pilot study will inform intervention refinement for a future fully-powered clinical trial, as well as other implementation and research efforts supporting care transitions for people with SUD. Trial registration: Clinicaltrials.gov NCT07575373
- 24 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0359281
Open AccessFeasibility of an interdisciplinary primary care-based intervention to improve care transitions for hospitalized patients with substance use disorders: The IntACT pilot randomized controlled trial protocol
Background: Hospitalizations are common among individuals with substance use disorders (SUD) and represent crucial opportunities to engage patients in treatment. Quality efforts to increase SUD treatment access in hospital settings must be paired with interventions that support linkage to follow-up SUD and medical care. However, the best way to support patients with SUD during transitions of care after hospitalization is unknown. Methods: The IntACT pilot study is a single-site randomized controlled trial that aims to assess the feasibility and preliminary effectiveness of a primary care-based Interdisciplinary Addiction Care Transition (IntACT) team. IntACT deploys from a partnering primary care clinic to the hospital to meet patients with SUD while they are admitted, then follows them after discharge for four months to facilitate linkage to and retention in follow-up care. The pilot study will randomize 75 hospitalized patients with SUD to receive IntACT or Usual Care, assessing both implementation and effectiveness outcomes over a six month study period. Primary outcomes include implementation measures (e.g., reach, acceptability, feasibility, and cost) assessed using a mixed methods approach, as well as preliminary measures of effectiveness including successful linkage to follow-up medical and/or SUD care after hospitalization and retention in treatment. Secondary effectiveness measures include time to first post-discharge follow-up visit, substance use patterns, and acute care utilization (e.g., hospital readmissions). The IntACT study will also enroll 20 clinicians from hospital and outpatient settings who interact with IntACT while providing patient care to provide input on intervention feasibility, appropriateness, and acceptability. Study design and procedural elements will also be assessed for feasibility and acceptability. Discussion: Identifying promising interventions to support transitions to follow-up SUD and medical care following hospitalization is imperative to increase SUD treatment access and improve care quality. The IntACT pilot study evaluates the feasibility of a novel, potentially scalable team-based care transition intervention, gathering implementation data from both patients and clinicians who are exposed to the intervention. The results of this pilot study will inform intervention refinement for a future fully-powered clinical trial, as well as other implementation and research efforts supporting care transitions for people with SUD. Trial registration: Clinicaltrials.gov NCT07575373
- 13 July 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (4) , 995-1005
Upstream Overdose Prevention: Why the US Should Pilot a Safer, Regulated Drug Supply
The United States overdose crisis is driven in large part by an increasingly unpredictable and contaminated drug supply, including fentanyl and its analogs and emerging adulterants such as xylazine and nitazenes. Drug checking interventions such as fentanyl test strips and Fourier Transform Infrared Spectroscopy are essential for harm reduction, yet they also highlight a central policy failure: they place the burden of safety on people who use drugs (PWUD) and frontline programs after drugs have already entered an unregulated market. We argue for a more pragmatic upstream public health response, authorizing pilots of a safer, regulated drug supply (“safer supply”), broadly defined as legal and regulated access to psychoactive substances or close pharmaceutical alternatives intended to reduce reliance on the unregulated drug market. International experience, particularly models in Switzerland, Canada, and the United Kingdom, demonstrates feasibility and suggests potential benefits, including improved health and social stability, reduced reliance on unregulated supply, and reduced acute care utilization in some settings. For the United States context, we propose a portfolio approach: near-term, healthcare-based pilots leveraging existing controlled-substance infrastructure (eg, opioid treatment programs, clinics, pharmacies, and tech-enabled dispensing) while preserving space for community-governed models with legal protections and longer-horizon, state-regulated pathways. We address predictable concerns (secondary sharing, youth initiation, community impact, mixed population-level findings) and outline guardrails and evaluation strategies that are PWUD-led, nonpunitive, and methodologically rigorous. We conclude with concrete policy actions to authorize pilots, establish legal protections, fund independent evaluation, and scale models that demonstrably reduce harm while integrating with harm reduction and treatment services.
- 13 July 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (4) , 995-1005
Upstream Overdose Prevention: Why the US Should Pilot a Safer, Regulated Drug Supply
The United States overdose crisis is driven in large part by an increasingly unpredictable and contaminated drug supply, including fentanyl and its analogs and emerging adulterants such as xylazine and nitazenes. Drug checking interventions such as fentanyl test strips and Fourier Transform Infrared Spectroscopy are essential for harm reduction, yet they also highlight a central policy failure: they place the burden of safety on people who use drugs (PWUD) and frontline programs after drugs have already entered an unregulated market. We argue for a more pragmatic upstream public health response, authorizing pilots of a safer, regulated drug supply (“safer supply”), broadly defined as legal and regulated access to psychoactive substances or close pharmaceutical alternatives intended to reduce reliance on the unregulated drug market. International experience, particularly models in Switzerland, Canada, and the United Kingdom, demonstrates feasibility and suggests potential benefits, including improved health and social stability, reduced reliance on unregulated supply, and reduced acute care utilization in some settings. For the United States context, we propose a portfolio approach: near-term, healthcare-based pilots leveraging existing controlled-substance infrastructure (eg, opioid treatment programs, clinics, pharmacies, and tech-enabled dispensing) while preserving space for community-governed models with legal protections and longer-horizon, state-regulated pathways. We address predictable concerns (secondary sharing, youth initiation, community impact, mixed population-level findings) and outline guardrails and evaluation strategies that are PWUD-led, nonpunitive, and methodologically rigorous. We conclude with concrete policy actions to authorize pilots, establish legal protections, fund independent evaluation, and scale models that demonstrably reduce harm while integrating with harm reduction and treatment services.
- Open Access
Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial
Background and aims: Individuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care‐integrated collaborative care approach for reducing risky opioid use, defined as nonmedical use of prescription opioids or any use of illicit opioids. Design: Cluster‐randomized controlled trial randomized primary care providers (PCPs) and their patients into the Subthreshold Opioid Use Disorder Prevention (STOP) intervention or enhanced usual care (EUC). Setting: Primary care clinics at 5 U.S. sites. Participants: PCPs and their patients were recruited January 2021–May 2023. A total of 119 PCP clusters (STOP = 48, EUC = 51) and 202 patients (STOP = 88, EUC = 114) enrolled. Eligible patients were adults (≥18 years) having current risky opioid use, without moderate–severe OUD. Patient participants were majority female (63.4%), white (70.8%) and non‐Hispanic (96.5%), with a mean age of 55.7 [standard deviation (SD) = 12.7] years. At baseline, 63.4% of participants had moderate–severe pain (Brief Pain Inventory) and below average physical (79.2%) and mental (62.4%) health (SF‐12). Interventions: The STOP collaborative care intervention consisted of brief advice from the PCP about reducing risky opioid use, meetings with a clinic‐embedded nurse care manager over 12 months and remote health coaching (2–6 sessions). Both groups received primary care treatment as usual and overdose risk reduction materials. Measurements: The primary outcome was total days of risky opioid use, recorded from 6 monthly electronic surveys. A key secondary outcome was moderate–severe OUD at 6 and 12 months. Findings: A total of 77 (87.5%) STOP and 107 (93.9%) EUC participants completed the 6‐month assessment period. The primary outcome analysis used the Intention‐to‐Treat sample with multiple imputations of missing data. Mean days of risky opioid use at 180 days were lower in STOP than EUC [12.2 (SD = 27.73) vs. 15.5 (SD = 32.64)]; the difference between groups adjusted for baseline risky opioid use was not statistically significant (rate ratio 0.95, 95% confidence interval = 0.52–1.74). One STOP participant (1.1%) and 13 EUC participants (11.4%) developed moderate–severe OUD at 6 months, and 3 (3.4%) STOP and 6 (5.3%) EUC participants had moderate–severe OUD at 12 months ( P < 0.001). Conclusions: This cluster‐randomized controlled trial did not find evidence that the STOP intervention for reducing risky opioid use produced greater reductions over 6 months compared with enhanced usual care, though fewer intervention participants progressed to moderate–severe opioid use disorder. Patients had a high burden of pain and comorbidities that may present challenges to reducing opioid use.
Open AccessCollaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial
Background and aims: Individuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care‐integrated collaborative care approach for reducing risky opioid use, defined as nonmedical use of prescription opioids or any use of illicit opioids. Design: Cluster‐randomized controlled trial randomized primary care providers (PCPs) and their patients into the Subthreshold Opioid Use Disorder Prevention (STOP) intervention or enhanced usual care (EUC). Setting: Primary care clinics at 5 U.S. sites. Participants: PCPs and their patients were recruited January 2021–May 2023. A total of 119 PCP clusters (STOP = 48, EUC = 51) and 202 patients (STOP = 88, EUC = 114) enrolled. Eligible patients were adults (≥18 years) having current risky opioid use, without moderate–severe OUD. Patient participants were majority female (63.4%), white (70.8%) and non‐Hispanic (96.5%), with a mean age of 55.7 [standard deviation (SD) = 12.7] years. At baseline, 63.4% of participants had moderate–severe pain (Brief Pain Inventory) and below average physical (79.2%) and mental (62.4%) health (SF‐12). Interventions: The STOP collaborative care intervention consisted of brief advice from the PCP about reducing risky opioid use, meetings with a clinic‐embedded nurse care manager over 12 months and remote health coaching (2–6 sessions). Both groups received primary care treatment as usual and overdose risk reduction materials. Measurements: The primary outcome was total days of risky opioid use, recorded from 6 monthly electronic surveys. A key secondary outcome was moderate–severe OUD at 6 and 12 months. Findings: A total of 77 (87.5%) STOP and 107 (93.9%) EUC participants completed the 6‐month assessment period. The primary outcome analysis used the Intention‐to‐Treat sample with multiple imputations of missing data. Mean days of risky opioid use at 180 days were lower in STOP than EUC [12.2 (SD = 27.73) vs. 15.5 (SD = 32.64)]; the difference between groups adjusted for baseline risky opioid use was not statistically significant (rate ratio 0.95, 95% confidence interval = 0.52–1.74). One STOP participant (1.1%) and 13 EUC participants (11.4%) developed moderate–severe OUD at 6 months, and 3 (3.4%) STOP and 6 (5.3%) EUC participants had moderate–severe OUD at 12 months ( P < 0.001). Conclusions: This cluster‐randomized controlled trial did not find evidence that the STOP intervention for reducing risky opioid use produced greater reductions over 6 months compared with enhanced usual care, though fewer intervention participants progressed to moderate–severe opioid use disorder. Patients had a high burden of pain and comorbidities that may present challenges to reducing opioid use.
- Open Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2611711
Coverage Limitations for Use of Urine Drug Testing in a State Medicaid Program
Importance: Urine drug testing (UDT) is commonly used in substance use disorder (SUD) treatment. However, there is little evidence to guide optimal use of UDT and growing concern that some UDT may represent low-value care. Objective: To determine whether a statewide policy limiting Medicaid reimbursement for UDT is associated with testing frequency, expenditures, and clinical outcomes. Design, Setting, and Participants: This serial cross-sectional study was performed among Louisiana Medicaid beneficiaries between July 1, 2017, and February 29, 2020. Data were analyzed from November 1, 2024, to November 30, 2025. For each outcome, best-fit lines for pre-enactment trends were constructed and used to estimate postenactment trends, which were then compared with observed trends. The 3-way interaction of time by intervention period by outcome was analyzed to assess changes for each UDT utilization outcome compared with a matched control procedure (colonoscopy). Concomitant trends in overdose encounters and prescription of medications for opioid use disorder (MOUD) were also assessed. Exposure: Statewide policy limiting Medicaid reimbursement for UDT enacted in July 2019. Colonoscopy rates were used as a temporal comparison procedure. Main Outcomes and Measures: Outcomes included rates of monthly UDT (total, presumptive, and definitive) and expenditures per 1000 beneficiaries for 24 months before and 7 months after policy enactment. Results: The sample included a total of 900 678 unique Medicaid-eligible beneficiaries, 536 841 (59.6%) of whom were female and 606 012 (67.3%) were younger than 40 years. Following policy enactment, the monthly rate of change for total UDT utilization decreased from 0.67 (95% CI, 0.48- 0.85) to −1.03 (95% CI, −1.65 to −0.40) tests per month per 1000 beneficiaries (difference, −1.70 [95% CI, −2.34 to −1.06] tests per month per 1000 beneficiaries); presumptive UDT decreased from 0.42 (95% CI, 0.30-0.53) to −0.63 (95% CI, −0.92 to −0.35) tests per month per 1000 beneficiaries (difference, −1.05 [95% CI, −1.36 to −0.74] tests per month per 1000 beneficiaries); and definitive UDT decreased from 0.25 (95% CI, 0.17-0.34) to −0.39 (95% CI, −0.97 to 0.18) tests per month per 1000 beneficiaries (difference, −0.65 [95% CI, −1.23 to −0.07] tests per month per 1000 beneficiaries). These decreases were all statistically significant compared with colonoscopy (all P < .05). UDT expenditures also significantly decreased, totaling an estimated $14.8 million in savings during the 7-month postenactment period. The policy change was not associated with reduced MOUD receipt or increased overdose encounters. Conclusion and Relevance: In this cross-sectional study, a state policy limiting reimbursement for UDT was associated with significant reductions in UDT utilization and expenditures. Future research and policymaking should investigate ways to optimize UDT for patient health while reducing low-value care.
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2611711
Open AccessCoverage Limitations for Use of Urine Drug Testing in a State Medicaid Program
Importance: Urine drug testing (UDT) is commonly used in substance use disorder (SUD) treatment. However, there is little evidence to guide optimal use of UDT and growing concern that some UDT may represent low-value care. Objective: To determine whether a statewide policy limiting Medicaid reimbursement for UDT is associated with testing frequency, expenditures, and clinical outcomes. Design, Setting, and Participants: This serial cross-sectional study was performed among Louisiana Medicaid beneficiaries between July 1, 2017, and February 29, 2020. Data were analyzed from November 1, 2024, to November 30, 2025. For each outcome, best-fit lines for pre-enactment trends were constructed and used to estimate postenactment trends, which were then compared with observed trends. The 3-way interaction of time by intervention period by outcome was analyzed to assess changes for each UDT utilization outcome compared with a matched control procedure (colonoscopy). Concomitant trends in overdose encounters and prescription of medications for opioid use disorder (MOUD) were also assessed. Exposure: Statewide policy limiting Medicaid reimbursement for UDT enacted in July 2019. Colonoscopy rates were used as a temporal comparison procedure. Main Outcomes and Measures: Outcomes included rates of monthly UDT (total, presumptive, and definitive) and expenditures per 1000 beneficiaries for 24 months before and 7 months after policy enactment. Results: The sample included a total of 900 678 unique Medicaid-eligible beneficiaries, 536 841 (59.6%) of whom were female and 606 012 (67.3%) were younger than 40 years. Following policy enactment, the monthly rate of change for total UDT utilization decreased from 0.67 (95% CI, 0.48- 0.85) to −1.03 (95% CI, −1.65 to −0.40) tests per month per 1000 beneficiaries (difference, −1.70 [95% CI, −2.34 to −1.06] tests per month per 1000 beneficiaries); presumptive UDT decreased from 0.42 (95% CI, 0.30-0.53) to −0.63 (95% CI, −0.92 to −0.35) tests per month per 1000 beneficiaries (difference, −1.05 [95% CI, −1.36 to −0.74] tests per month per 1000 beneficiaries); and definitive UDT decreased from 0.25 (95% CI, 0.17-0.34) to −0.39 (95% CI, −0.97 to 0.18) tests per month per 1000 beneficiaries (difference, −0.65 [95% CI, −1.23 to −0.07] tests per month per 1000 beneficiaries). These decreases were all statistically significant compared with colonoscopy (all P < .05). UDT expenditures also significantly decreased, totaling an estimated $14.8 million in savings during the 7-month postenactment period. The policy change was not associated with reduced MOUD receipt or increased overdose encounters. Conclusion and Relevance: In this cross-sectional study, a state policy limiting reimbursement for UDT was associated with significant reductions in UDT utilization and expenditures. Future research and policymaking should investigate ways to optimize UDT for patient health while reducing low-value care.
- 4 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 617-627
Building Stronger Communities Through Addiction Care Innovation, Research, Education, and Advocacy—Overview and Proceedings of the AMERSA 2025 Conference
This commentary provides an overview of the 49th annual AMERSA conference, held from November 13 to 15, 2025, in Portland, OR. The conference featured 16 interactive workshops, over 160 oral abstract presentations, and 120 poster presentations. In alignment with the theme of Building Stronger Communities through Addiction Care Innovation, Research, Education and Advocacy, the conference program planning committee was committed to incorporating sessions, including plenaries, workshops, and abstract presentations, which focused on expanding access to resources and including community voices. Plenary topics included building rural peer networks to expand the reach of substance use and substance use disorder care, supportive housing, expanding access to medications for opioid use disorder in rural areas, and the use of psychedelics as an emerging treatment modality, among others. Workshops addressed topics such as building partnerships between academic and tribal communities, Community Reinforcement and Family Training for practitioners, addressing stigma associated with substance use, and strategies to access difficult-to-reach populations to provide care. Through session attendance and dialogue with peers from across geographies and disciplines, the conference created space for conversations that cut across silos and helped to shape evidence-informed, community-engaged practice.
- 4 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 617-627
Building Stronger Communities Through Addiction Care Innovation, Research, Education, and Advocacy—Overview and Proceedings of the AMERSA 2025 Conference
This commentary provides an overview of the 49th annual AMERSA conference, held from November 13 to 15, 2025, in Portland, OR. The conference featured 16 interactive workshops, over 160 oral abstract presentations, and 120 poster presentations. In alignment with the theme of Building Stronger Communities through Addiction Care Innovation, Research, Education and Advocacy, the conference program planning committee was committed to incorporating sessions, including plenaries, workshops, and abstract presentations, which focused on expanding access to resources and including community voices. Plenary topics included building rural peer networks to expand the reach of substance use and substance use disorder care, supportive housing, expanding access to medications for opioid use disorder in rural areas, and the use of psychedelics as an emerging treatment modality, among others. Workshops addressed topics such as building partnerships between academic and tribal communities, Community Reinforcement and Family Training for practitioners, addressing stigma associated with substance use, and strategies to access difficult-to-reach populations to provide care. Through session attendance and dialogue with peers from across geographies and disciplines, the conference created space for conversations that cut across silos and helped to shape evidence-informed, community-engaged practice.
- Open Access
- 28 February 2026
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 106 (4)
Primary care provider attitudes regarding physical therapists addressing opioid use and opioid misuse: a qualitative study
Importance: Primary care providers (PCPs) manage musculoskeletal pain and may prescribe opioids for their patients, presenting risk for opioid misuse. Physical therapists are well-positioned to collaborate with PCPs in identifying and mitigating opioid risk and misuse for patients that PCPs and physical therapists co-manage. How PCPs view such collaboration is unclear. Objective: The objective of this study was to explore PCPs’ attitudes regarding physical therapists’ role in identifying and mitigating opioid risk and opioid misuse. Design: This was a qualitative study using rapid content analysis and it was the first phase in a sequential exploratory mixed-methods investigation. Setting and participants: Semi-structured interviews were conducted with 22 PCPs in Utah. PCPs were invited to participate if they were listed by the Utah Division of Professional Licensure as having an active license to practice in Utah. PCPs were eligible to participate if they (1) referred a patient to outpatient physical therapy within the past 6 months and (2) prescribed an opioid within the past 6 months. Interviews were conducted between May 6, 2024, and August 9, 2024, and were audio recorded and transcribed. Main Outcome: The main outcomes were qualitative themes reported by the PCPs surrounding their attitudes toward collaborating with physical therapists on patients taking prescription opioid medication for pain. Results: Twenty-two PCPs were interviewed, which included 7 (31.8%) physicians, 6 (27.3%) nurse practitioners, and 9 (40.9%) physician assistants. Mean years of clinical experience was 13.9 (SD = 9.1) with 12 (56.0%) participants identifying as female and 20 (90.1%) identifying as White. The themes identified were (1) physical therapist’s involvement in opioid management can help patients, (2) communication between physical therapists and PCPs regarding opioids is important, (3) physical therapists should educate their patients about the risks of opioid use, and (4) physical therapists should refer their patients with suspected opioid misuse for further management. Conclusion and relevance: PCPs favorably regarded physical therapists’ involvement in identifying and mitigating opioid risk and misuse among co-managed patients.
- 28 February 2026
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 106 (4)
Open AccessPrimary care provider attitudes regarding physical therapists addressing opioid use and opioid misuse: a qualitative study
Importance: Primary care providers (PCPs) manage musculoskeletal pain and may prescribe opioids for their patients, presenting risk for opioid misuse. Physical therapists are well-positioned to collaborate with PCPs in identifying and mitigating opioid risk and misuse for patients that PCPs and physical therapists co-manage. How PCPs view such collaboration is unclear. Objective: The objective of this study was to explore PCPs’ attitudes regarding physical therapists’ role in identifying and mitigating opioid risk and opioid misuse. Design: This was a qualitative study using rapid content analysis and it was the first phase in a sequential exploratory mixed-methods investigation. Setting and participants: Semi-structured interviews were conducted with 22 PCPs in Utah. PCPs were invited to participate if they were listed by the Utah Division of Professional Licensure as having an active license to practice in Utah. PCPs were eligible to participate if they (1) referred a patient to outpatient physical therapy within the past 6 months and (2) prescribed an opioid within the past 6 months. Interviews were conducted between May 6, 2024, and August 9, 2024, and were audio recorded and transcribed. Main Outcome: The main outcomes were qualitative themes reported by the PCPs surrounding their attitudes toward collaborating with physical therapists on patients taking prescription opioid medication for pain. Results: Twenty-two PCPs were interviewed, which included 7 (31.8%) physicians, 6 (27.3%) nurse practitioners, and 9 (40.9%) physician assistants. Mean years of clinical experience was 13.9 (SD = 9.1) with 12 (56.0%) participants identifying as female and 20 (90.1%) identifying as White. The themes identified were (1) physical therapist’s involvement in opioid management can help patients, (2) communication between physical therapists and PCPs regarding opioids is important, (3) physical therapists should educate their patients about the risks of opioid use, and (4) physical therapists should refer their patients with suspected opioid misuse for further management. Conclusion and relevance: PCPs favorably regarded physical therapists’ involvement in identifying and mitigating opioid risk and misuse among co-managed patients.
- 7 November 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (2) , 309-315
In Support of a Public Health Approach to Drug Policy: Position Statement of AMERSA, Inc
The United States faces a profound overdose crisis and a volatile, unregulated drug supply. Despite the availability of effective treatments and harm reduction strategies, many individuals who use drugs have limited access to evidence-based interventions. Punitive approaches to people who use drugs have worsened the situation. In this position statement, we assert that there is a critical need for drug policies to be grounded in public health evidence rather than punitive measures. We focus on 2 case studies to exemplify this idea: (1) xylazine scheduling laws and (2) drug-induced homicide laws. Ultimately, the Association for Multidisciplinary Education and Research in Substance Use and Addiction advocates for a public health approach to drug policy, which is based on the tenets of harm reduction. The organization opposes punitive measures and promotes policies that improve access to healthcare and harm reduction services.
- 7 November 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (2) , 309-315
In Support of a Public Health Approach to Drug Policy: Position Statement of AMERSA, Inc
The United States faces a profound overdose crisis and a volatile, unregulated drug supply. Despite the availability of effective treatments and harm reduction strategies, many individuals who use drugs have limited access to evidence-based interventions. Punitive approaches to people who use drugs have worsened the situation. In this position statement, we assert that there is a critical need for drug policies to be grounded in public health evidence rather than punitive measures. We focus on 2 case studies to exemplify this idea: (1) xylazine scheduling laws and (2) drug-induced homicide laws. Ultimately, the Association for Multidisciplinary Education and Research in Substance Use and Addiction advocates for a public health approach to drug policy, which is based on the tenets of harm reduction. The organization opposes punitive measures and promotes policies that improve access to healthcare and harm reduction services.
- 25 August 2025
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- p. 209797
Factors associated with mortality following hospitalization among veterans with opioid use disorder
- 25 August 2025
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- p. 209797
Factors associated with mortality following hospitalization among veterans with opioid use disorder